| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Other Events
As previously reported, on November 5, 2026, Precision BioSciences, Inc. (the “Company”) entered into an underwriting agreement relating to the issuance and sale by the Company of 10,235,077 shares of its common stock, $0.000005 par valu... |
| 06 Nov 2026 |
8-K: Other Events
Exhibit 1.1 Precision BioSciences, Inc. 10,235,077 Shares of Common Stock, par value $0.000005 per share and Pre-Funded Warrants to Purchase up to 5,893,964 Shares of Common Stock Underwriting Agreement November 5, 2026 TD Securities (US... |
| 05 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
AASLD 2026 Investor Update: Direct cccDNA Elimination Leads to an Era of Potential Chronic Hepatitis B Viral Cure Confidential |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
- PBGENE-HBV late-breaking oral presentation for ELIMINATE-B trial at AASLD's The Liver Meeting® 2026 on November 8; data abstract scheduled for release November 5 - |
| 24 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
-First patient dosed with PBGENE-DMD, the first clinical gene-editing program for DMD – |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining - |
| 27 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones |
| 01 Jul 2026 |
8-K: Regulation FD Disclosure; Other Events
Precision BioSciences, Inc. (the “Company”) has updated its corporate deck, which is available in the “Investors” portion of the Company’s website at https://investor.precisionbiosciences.com. |
| 16 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
This First Amendment to Amended and Restated Loan and Security Agreement (this “Amendment”) is made and entered into as of June 10, 2026 by and among BANC OF CALIFORNIA, a California state-chartered bank (“Bank”), and PRECISION BIOSCIENC... |
| 27 May 2026 |
8-K: Regulation FD Disclosure; Other Events
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 |
| 26 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. ... |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
-Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association for the Study of the Liver Congress 2026 - |
| 17 Mar 2026 |
8-K: Regulation FD Disclosure
Precision BioSciences PBGENE-DMD Investor Update March 17, 2026 |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
- PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity - |
| 11 Feb 2026 |
8-K: Regulation FD Disclosure; Other Events
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy |
| 13 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy |
| 12 Nov 2025 |
8-K: Other Events
Precision BioSciences, Inc.10,815,000 Shares of Common Stock, par value $0.000005 per share, |
| 10 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition
Late-breaking oral presentation at the Liver Meeting® 2025 to feature new data from multiple cohorts of the Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B |
| 02 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 26, 2025, Precision BioSciences, Inc. (the “Company”) entered into amended and restated employment agreements to help retain each of its Section 16 officers: Michael Amoroso, the Company’s President and Chief Executive Officer;... |
Loading...